1. China Stocks

  2. •

    Health technology

  3. •

    Pharmaceuticals: major
Jiangsu Hengrui Pharmaceuticals Co., Ltd. Class A

Jiangsu Hengrui Pharmaceuticals Co., Ltd. Class A

5.45
EUR
-0.20
(-3.54%)
0.17EPS
38.80P/E
49.58BMarket Cap
Oct 27Next Earn
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
0.88
1.05
1.31
1.56
1.93
2.44
3.24
3.86
3.61
2.96
3.21
3.93
4.35
4.79
Basic EPS, GAAP
0.17
0.21
0.31
0.36
0.45
0.57
0.74
0.88
0.63
0.54
0.61
0.89
1.06
1.33
Free Cash Flow per Basic Share
0.13
0.18
0.26
0.21
0.3
0.31
0.45
0.4
0.36
-0.1
0.87
0.77
1.14
- -
Dividend per Share
0.01
0.02
0.02
0.03
0.04
0.05
0.11
0.14
0.15
0.14
0.14
0.18
0.18
- -
Book Value per Share
0.9
1.1
1.4
1.74
2.16
2.78
3.46
4.24
4.87
5.28
5.65
6.35
8.22
8.65
Tangible Book Value per Share
0.87
1.07
1.37
1.7
2.12
2.74
3.41
4.2
4.77
4.97
5.18
5.65
7.3
7.58
Basic Weighted Avg Shares
7,088
7,080
7,112
7,100
7,176
7,148
7,181
7,180
7,167
7,193
7,107
7,117
7,278
6,775
Sales/Revenue/Turnover
6,203
7,452
9,316
11,094
13,836
17,418
23,289
27,735
25,906
21,275
22,820
27,985
31,629
32,453
Operating Margin (%)
23.03
22.79
25.98
25.59
27.07
24.39
24.42
23.36
15.76
15.72
20.27
24.31
27.18
28.93
Depreciation Expense
171
213
222
254
317
379
619
448
520
578
705
776
845
- -
Net Income, GAAP
1,238
1,516
2,172
2,589
3,217
4,066
5,328
6,328
4,530
3,906
4,302
6,337
7,711
9,001
Effective Tax Rate (%)
12.61
12.6
13.19
12.58
12.4
9.73
12.04
8.51
- -
3.86
8.34
11.61
11.38
11.96
Profit Margin (%)
19.96
20.34
23.31
23.34
23.25
23.34
22.88
22.82
17.49
18.36
18.85
22.64
24.38
27.74
Working Capital
4,927
6,349
8,325
10,028
12,418
15,785
19,839
24,278
26,786
27,295
28,734
31,681
45,121
45,360
LT Debt
10
10
- -
- -
- -
- -
- -
- -
152
99
75
69
43
38
Total Equity
6,656
8,154
10,358
12,874
15,943
19,925
24,938
30,787
35,572
38,413
41,033
46,090
61,797
64,990
Return on Invested Capital (%)
20.71
20.62
23.57
22.3
22.58
22.79
23.99
22.9
- -
10.46
11.11
15.08
14.59
16.34
Return on Capital (%)
19.53
19.65
22.87
21.89
21.57
22.72
23.79
22.8
- -
10.61
10.71
14.53
14.28
15.98
Return on Common Equity (%)
21.4
21.41
24.5
23.2
23.18
23.08
23.88
22.9
13.83
10.73
10.99
14.74
14.44
16.15

Capital Structure

CNY

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
ST Debt
31
30
30
LT Borrowings
- -
- -
- -
LT Finance Leases
43
37
38
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
7,455
7,455
7,455
Market Capitalization
474,890
422,018
384,269

Working Capital

CNY

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
Total Current Assets
51,490
52,044
49,608
Cash, Cash Equivalents & STI
41,069
40,636
38,842
Accounts Receivable, Net
5,147
5,021
4,920
Inventories
2,878
2,886
2,994
Total Current Liabilities
6,369
5,637
4,247
Payables & Accruals
- -
- -
- -
ST Debt
31
30
30
Deferred Revenue
- -
- -
- -

Growth Rates

CNY

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
19.85%
15.35%
34.08%
Free Cash Flow
-98.49%
-209.37%
51.71%
Net Income, GAAP
15.66%
7.39%
21.69%
Sales/Revenue/Turnover
14.09%
3.69%
13.02%
Total Cash Common Dividend
28%
5.23%
0.74%

Quarterly Revenue

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
5,998
7,603
6,589
7,795
27,985
2025
7,206
8,556
- -
8,441
31,629
2026
8,141
7,315
- -
- -
- -

Quarterly Earnings Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.19
0.32
0.19
0.27
0.89
2025
0.27
0.4
- -
0.3
1.06
2026
0.3
0.33
- -
- -
- -

Quarterly Dividends Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
0.2
- -
0.18
2025
- -
- -
- -
- -
0.18
2026
- -
- -
- -
- -
- -

Company Description

Company Profile APIChatGPT
CEO
Sun Piaoyang
Full Time Employees
20,602
Sector
Health technology
Industry
Pharmaceuticals: major
Address
No. 38, Huanghe Road Lianyungang JS China 222047
IPO Date
Oct 18, 2000
Website
hengrui.com
Similar Companies
Eli Lilly and Company (NYSE:LLY)
Novo Nordisk A/S (NYSE:NVO)
Johnson & Johnson (NYSE:JNJ)
Pfizer, Inc. (NYSE:PFE)
Dr. Reddy's Laboratories Ltd. (NSE:DRREDDY)
Divi's Laboratories Limited (NSE:DIVISLAB)
Business
Jiangsu Hengrui Pharmaceuticals Co., Ltd. (600276.SS; 1276.HK) develops, manufactures and markets innovative pharmaceuticals targeting oncology, metabolic and cardiovascular diseases, immunology and respiratory conditions, neuroscience, anesthesia, anti-infection and autoimmune disorders; its core products encompass new molecular entity drugs such as Apalutamide, Nab-paclitaxel (Hengli) and Otilimab, alongside surgical medicines, endocrine therapies, cardiovascular drugs, contrast agents, proteolysis-targeting chimeras (PROTACs), peptides, monoclonal antibodies, bispecific antibodies (BsAbs), antibody-drug conjugates (ADCs) and radioligand therapies. Founded in 1970 and headquartered in Lianyungang, Jiangsu province, China, the company operates globally with R&D centers in China, the United States, Japan, Australia and Switzerland, subsidiaries in the US and Europe, and products available in over 40 countries including emerging markets; it maintains a pipeline of more than 100 innovative candidates across 400 clinical trials worldwide. In July 2025, Hengrui entered a landmark $500 million upfront collaboration with GSK to exclusively license HRS-9821 for chronic obstructive pulmonary disease and up to 11 additional preclinical candidates in respiratory, immunology, inflammation and oncology, with total potential value exceeding $12 billion; additional recent deals include a March 2025 agreement with Merck & Co. for oral lipoprotein(a) inhibitor HRS-5346 worth up to $1.97 billion and a May 2025 Hong Kong IPO raising $1.27 billion, alongside an exclusive license with Glenmark Pharmaceuticals for HER2 ADC Trastuzumab Rezetecan (SHR-A1811).